184 related articles for article (PubMed ID: 33895188)
1. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development.
Peerzada MN; Hamel E; Bai R; Supuran CT; Azam A
Pharmacol Ther; 2021 Sep; 225():107860. PubMed ID: 33895188
[TBL] [Abstract][Full Text] [Related]
2. Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets.
Mushtaq A; Wu P; Naseer MM
Pharmacol Ther; 2024 Feb; 254():108579. PubMed ID: 38160914
[TBL] [Abstract][Full Text] [Related]
3. Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
Kharb R
Anticancer Agents Med Chem; 2021; 21(11):1338-1349. PubMed ID: 32560614
[TBL] [Abstract][Full Text] [Related]
4. Carbonic anhydrase inhibitors. Synthesis of heterocyclic 4-substituted pyridine-3-sulfonamide derivatives and their inhibition of the human cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
Sławiński J; Szafrański K; Vullo D; Supuran CT
Eur J Med Chem; 2013 Nov; 69():701-10. PubMed ID: 24095761
[TBL] [Abstract][Full Text] [Related]
5. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
Nehra B; Mathew B; Chawla PA
Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
[TBL] [Abstract][Full Text] [Related]
6. Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.
Ion GND; Olaru OT; Nitulescu G; Olaru II; Tsatsakis A; Burykina TI; Spandidos DA; Nitulescu GM
Oncol Rep; 2020 Aug; 44(2):589-598. PubMed ID: 32627025
[TBL] [Abstract][Full Text] [Related]
7. Indazole Derivatives: Promising Anti-tumor Agents.
Wan Y; He S; Li W; Tang Z
Anticancer Agents Med Chem; 2018; 18(9):1228-1234. PubMed ID: 29745343
[TBL] [Abstract][Full Text] [Related]
8. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
Haider K; Rahaman S; Yar MS; Kamal A
Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
[No Abstract] [Full Text] [Related]
9. Heterocyclic compounds as carbonic anhydrase inhibitor.
Husain A; Madhesia D
J Enzyme Inhib Med Chem; 2012 Dec; 27(6):773-83. PubMed ID: 21981003
[TBL] [Abstract][Full Text] [Related]
10. Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.
Gao R; Liao S; Zhang C; Zhu W; Wang L; Huang J; Zhao Z; Li H; Qian X; Xu Y
Eur J Med Chem; 2013 Apr; 62():597-604. PubMed ID: 23429054
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Therapeutic Potential of Anticancer Heterocyclic Compounds: Role in Nanoscale Pharmacotherapy.
Kumar L; Verma S; Joshi K; Sharma S
Crit Rev Ther Drug Carrier Syst; 2023; 40(3):47-94. PubMed ID: 36749083
[TBL] [Abstract][Full Text] [Related]
12. Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents.
Azad I; Nasibullah M; Khan T; Hassan F; Akhter Y
J Mol Graph Model; 2018 May; 81():211-228. PubMed ID: 29609141
[TBL] [Abstract][Full Text] [Related]
13. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).
Nocentini A; Supuran CT
Expert Opin Ther Pat; 2018 Oct; 28(10):729-740. PubMed ID: 30074415
[TBL] [Abstract][Full Text] [Related]
14. Novel diaryl or heterocyclic sulfonamides as antimitotic agents.
Hu L; Li ZR; Jiang JD; Boykin DW
Anticancer Agents Med Chem; 2008 Oct; 8(7):739-45. PubMed ID: 18855576
[TBL] [Abstract][Full Text] [Related]
15. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
Supuran CT
Expert Opin Investig Drugs; 2018 Dec; 27(12):963-970. PubMed ID: 30426805
[TBL] [Abstract][Full Text] [Related]
17. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations.
Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA
Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.
Penthala NR; Zong H; Ketkar A; Madadi NR; Janganati V; Eoff RL; Guzman ML; Crooks PA
Eur J Med Chem; 2015 Mar; 92():212-20. PubMed ID: 25557492
[TBL] [Abstract][Full Text] [Related]
19. Heterocyclic Scaffolds: Centrality in Anticancer Drug Development.
Ali I; Lone MN; Al-Othman ZA; Al-Warthan A; Sanagi MM
Curr Drug Targets; 2015; 16(7):711-34. PubMed ID: 25751009
[TBL] [Abstract][Full Text] [Related]
20. Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016).
Lomelino C; McKenna R
Expert Opin Ther Pat; 2016 Aug; 26(8):947-56. PubMed ID: 27387065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
